



CHARITY COMMISSION
FOR ENGLAND AND WALES

Trustees' Annual Report for the period

From 1/6/2023 Period start date To 31/5/2024 Period end date

Charity name: HaemSTAR: Haematology Specialist Training, Audit and Research

Charity registration number: 1199224

Objectives and Activities

	SORP reference	
Summary of the purposes of the charity as set out in its governing document	Para 1.17	To protect and preserve the health of patients suffering from haematological conditions by: - the promotion of clinical research into Non-Malignant Haematology in the United Kingdom, the causes, prevention and treatment of haematological conditions on terms that the results of such research will be published. - the advancement of education and training of junior doctors and haematologists to give them the skills to become the chief and principal investigators of the future.'
Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts.	Para 1.17 and 1.19	During 1/6/23 to 31/5/24 we conceived, developed, ran, supported and/or wrote up eighteen projects. All of these projects further our charitable objects because - they all require project management (which is used to train junior doctors and haematologists in how to be researchers and principal investigators) and - they ultimately result in the publication of research findings that benefit patients. Projects take several years to complete from the time of inception. Activities completed 1/6/23 to 31/4/23 are highlighted in red text. ITP Post COVID19 Vaccine Type of study: Retrospective Observational Study. Topic: Timing of onset, clinical characteristics, response to treatment and outcomes of patients with ITP developing following COVID19 vaccination. HaemSTAR role: Conceived and developed by Dr Quentin Hill (Leeds). Run and promoted by the ITP Forum and HaemSTAR. Data management provided by PHE. Funded by PHE. Size of study: Data collection completed in 2022. Size of Study: No results available as study yet to publish. Main outcomes: Data analysis ongoing. Outputs: yet to publish. ConNeCT: Type of study: Prospective Observational Study. Topic: Neurological, cognitive and neuropsychiatric complications of TTP.

		• HaemSTAR role: Conceived and developed by Dr Tina Dutt and Dr Rebecca Shaw (Liverpool). Run and promoted by the University of Liverpool and HaemSTAR. Data management provided by University of Liverpool. Funded by the Bayer Haemophilia Awards Programme. • Size of study: 211 patients and 50 healthy volunteers recruited. Patient recruitment completed Feb 2024. Data collection ongoing (planned completion Q1 2025). • Main outcomes: Interim analysis ongoing, likely complete Q1 2026. • Outputs: Yet to finish data collection A2PLS (Anticoagulation in Antiphospholipid Syndrome): • Type of study: Retrospective National Audit. • Topic: Compliance with BSH guidelines on management of antiphospholipid syndrome (APS). • HaemSTAR role: Conceived by Dr Deepa Arachchillage and Dr Christina Crossette-Thambiah (Imperial College). Developed and run in collaboration HaemSTAR. Data management provided by Imperial College. Funded by Bayer AG. • Size of study: Recruited 499 patients (Target 500) • Main outcomes: ○ Overall: 69% of patients anticoagulated with warfarin, 17% DOAC, 6% other, 8% not anticoagulated. ○ Triple Pos: 80% on warfarin. 10% DOACs. ○ Of those with arterial thrombosis: VKA 71%, DOAC 9%, other 19.6%. ○ Overall: 39% thrombosis recurrence over 10 years (Arterial recurrence more likely than venous). Triple vs dual vs single positive disease not predictive of recurrence ○ LAC most predictive marker of recurrence • Outputs: Oral Presentation at American Society of Hematology Annual Congress (New Orleans) Dec 2022 Manuscript in preparation, delayed due to some unforeseen devastating personal circumstances within the study steering group. BAT-X (Bleeding Assessment Tool in patients with X-linked agammaglobulinaemia [XLA]): • Type of study: Prospective Observational Study. • Topic: To establish whether patients with XLA have increased bleeding. • HaemSTAR role: Conceived, developed and run by Dr Pip Nicolson and Dr Chris Smith (Birmingham) and HaemSTAR. Data management provided by University of Birmingham. Funded by the British Heart Foundation (BHF). • Size of study: Recruited 42 patients • Main outcomes: Median ISTH-BAT Score of 1 (IQR 0-4). 14 participants had scores ≥ 4. Two of these had colitis, 3 patients were on antiplatelets / anticoagulants / NSAIDs. • Outputs: Manuscript in preparation 2SR (Two-Sample Rule Survey) • Type of study: Healthcare Practitioner Questionnaire
--	--	--

		• Topic: to establish attitudes towards and compliance with two (historic) sample rule in blood transfusion. • HaemSTAR role: Conceived by Dr Lorna Cain (Birmingham) and Dr Suzy Morton (Birmingham, NHSBT). Developed with the help of HaemSTAR. Data management provided by NHSBT. Funded by NHSBT. • Size of study: 209 responses across 22 hospitals. • Main outcomes: 96% aware of 2 sample rule in their hospital. 57% understand what the rule is. 55% understand the rationale for the rule. 60% admitted to going against the rule on more than one occasion. Non-compliant behaviour not associated with 2SR training or seniority. • Outputs: Oral Presentation at BSH ASM 2023. Manuscript in preparation. HaemSTAR RAPIDO (A 'Flash-Mob' UK national audit of the use of Reversal Agents in Patients anticoagulated with Direct Oral anticoagulants) • Type of study: Retrospective National Audit. • Topic: Compliance with BSH guidelines for the use of reversal agents in patients with major haemorrhage who are taking direct oral anticoagulants (DOACs). • HaemSTAR role: Conceived and developed by Dr Richard Buka (Stoke) and HaemSTAR. Run by HaemSTAR. Data management provided by BiCOPS. Funded by AstraZeneca and the Dudley Leukaemia Unit Appeal Fund. • Size of study: 2265 patients. • Main outcomes: 875 patients had GI haemorrhage, 1012 had ICH. Median age 81 years. Median time from bleed onset to reversal: 6.5 hours. Median time from last dose of anticoagulation to reversal: 16.0 hours. 1001 of 1253 non-ICH bleeds fulfilled criteria for major hemorrhage. Propensity score-matched analysis of 494 patients with GI haemorrhage: outcomes similar for andexanet alfa and four factor prothrombin complex concentrate. Incidence of stroke was significantly higher with andexanet alfa. • Outputs: Poster presentation at ASH Annual Congress 2024 and BSHT Annual Conference 2025. Manuscripts in preparation. MOM-ITP: Audit of management of neonatal ITP • Type of study: Prospective National Audit • Topic: Compliance with international consensus guidelines on management of pregnant women with ITP and neonatal ITP. • HaemSTAR role: Conceived and developed by dr Nick Fordham (Evelina Children's Hospital) and Dr Olga Tsiamita (Barts and HaemSTAR). Run by HaemSTAR. Data Management by HaemSTAR. Funded by Grifols. • Size of study: Target 100 patients. Recruitment ongoing (completion planned Q4 2025) • Main outcomes: data collection ongoing • Outputs: data collection ongoing TXA for HMB in acute VTE Tranexamic acid is an effective antifibrinolytic drug that can reduce heavy menstrual bleeding. Despite excellent safety data showing negligible increased risk of thrombosis across millions of patient years, its use in women with heavy menstrual bleeding who have a recent venous thromboembolic event remains controversial. The goal of this project is to work towards a pilot Randomised Control Trial.
--	--	--

		• Type of study: UK Clinician Survey • Topic: Clinical attitudes and practice towards use of tranexamic acid in female patients with menorrhagia who have previously experienced venous thromboembolism. • HaemSTAR role: Conceived and developed by Dr Eman Hassan (Birmingham and HaemSTAR). Distributed by HaemSTAR. Data analysis by Dr Hassan. Funding: nil. • Size of study: 102 respondents. • Main outcomes: Apixaban preferred anticoagulant for patients with HMB. Wide variation in practice re timing of TxA use; 35% prescribed it any time following initiation of anticoagulation, 12% delayed its use for 3 months; 8% would never give it. 47% of respondents advise to discontinue COCP following VTE (whilst treated with anticoagulants). 63% of respondents willing to participate in a study of TxA $\leq$ 4 weeks following VTE. • Outputs: Manuscript in preparation. • Type of study: Randomised Controlled Trial • Topic: Management of HMB in patients with VTE on anticoagulation. • HaemSTAR role: conceived and developed by Dr Eman Hassan (Birmingham and HaemSTAR) and Dr Gill Lowe (Birmingham and UK-TReN). • Progress: PICO submitted to UK NIHR HTA. Outcome awaited. MATRON (Maternal Audit on Thrombolysis Outcome and Decision) • Type of study: UK Clinician Survey & Retrospective Audit • Topic: The use of thrombolysis for pregnant women with venous thromboembolism. • Size of study: Survey with 70 responses. Target audit responses of 200 patients (completion Q2 2025). • HaemSTAR Role: Conceived and developed by Dr Giulia Simini (Royal London & HaemSTAR). Run by HaemSTAR. Data management by HaemSTAR. • Main outcomes: Survey: CDT available to 74%, Surgical thrombectomy to 62% and ECMO to 52% of respondents. Only 50% of sites had specific guidelines on CDT and 17% had no guidelines on managing pregnancy associated PE. 38% had received specific training on pregnancy-associated PE. 22% had had training in systemic thrombolysis. 46% did not have access to PERT with geographic inconsistency. Audit in planning stages. • Outputs: Survey manuscript in preparation. VAMP: Venesection vs Active Monitoring in Secondary Polycythaemia • Type of study: International clinician survey, retrospective audit and then prospective clinical trial. • Topic: Venesection in patients with idiopathic and secondary erythrocytosis • Size of study: Survey with 123 responses (90 senior clinicians). Audit with 206 patients. Prospective study in development. • HaemSTAR Role: Conceived and developed by Dr Richard Buka, Dr Bernard Maybury and Dr Pip Nicolson (Birmingham & HaemSTAR), Run by HaemSTAR, Data management by HaemSTAR. • Main outcomes:
--	--	---

		○ Survey: minority venesect routinely, 2/3 will venesect in specific circumstances; 1/3 never venesect. More likely to venesect if previous thrombosis or if headache or visual disturbance. Majority use Hct threshold of 0.55 but some use 0.6 and most have Hct target of <0.55 but some use <0.52. 85% willing to consider entering patients into a trial. ○ Audit: 2360 patients screened, 206 eligible, 27% no EPO done. Minority have RCM scan done. Most given appropriate lifestyle advice. 60% never venesected. 29% of those venesected have no target Hct documented. Mean Hct reduces prior to diagnosis and further reduces regardless of venesection. 5 year thrombosis rate 12% regardless of venesection vs no venesection or whether polycythaemia resolves. Cancer and prior unprovoked VTE are the only factors to predict subsequent thrombosis. • Outputs: Audit poster presentation at BSH 2024. Survey and Audit: manuscript in preparation. In set up: Apixaban thrombo-prophylaxis in multiple myeloma It is recommended that multiple myeloma patients treated with IMiDs such as thalidomide and lenalidomide be offered prophylactic anticoagulation due to the high risk of VTE. We understand that practice in the UK has shifted considerably and despite a lack of evidence, clinicians now favour the use of oral factor anti-Xa inhibitors, often apixaban, for this purpose. The aim of this project is to perform a retrospective, observational study to document thrombosis and bleeding outcomes in patients who receive this treatment compared to those who receive low molecular weight heparin. • Progress: Awaiting outcome of Myeloma UK grant application (as of 31/5/24) Anticoagulation at the end of life A survey is to gather data from secondary care clinicians in the UK on their management of anticoagulation in patients at the end of life. Perioperative management of Haemophilia B 'FIX-Surg' The primary objectives of the project are to audit the haemostatic management of patients with haemophilia B who are undergoing surgery against international guidelines (Srivastava et al., 2020). An Epidemiological Survey of Morbidity and Mortality in Patients Over the Age of 35 With Thalassaemia (Transfusion Dependent and Non-Transfusion Dependent) in England: SUMMIT Thalassaemia has historically been a severely life limiting disease with significant comorbid complications from an early age. As treatments, monitoring and awareness of this condition improve, so does quality of life and life expectancy. This study aims to assess whether patients over the age of 35 with thalassaemia are monitored in keeping with national guidelines, and to build a picture of the co-morbidities affecting patients with both transfusion and non-transfusion dependent thalassaemia over the age of 35 in the United Kingdom. FUNDING AWARDS From the ISTH Legacy Fund we were able to fund the conference attendances (see website for awardees).
--	--	--

		Application for award through competitive application with award by grant panel. Part of the ISTH Legacy Fund was to promote collaboration with LMIC (Nigeria) and help them develop their own trainee research network. In collaboration with NSHBT (Nigerian Society for Haematology and Blood Transfusion) they have founded HaemRYNE. Funds go towards infrastructure development and travel costs to promote educational visits within Nigeria and to UK. CONFERENCE In association with Hartley Taylor and the Post ISTH/ASH UK Update meeting we hosted a HaemSTAR Update day on 5/2/24 at Austin Court in Birmingham. This comprised updates and results on current HaemSTAR projects, plenary talks from experts including reflections on clinical/academic careers, management of HMB, CRISPR-Cas9, rural haematology as well as discussions about the role of the NIHR HTA. Very positive feedback. increased industry engagement from previous year. Increased attendance. Free registration HaemSTAR helped with travel reimbursement to enable attendance as well the time of the invited speakers. DISEASE THEMED WEBINARS Teamed up with 'The Limbic' to provide monthly online webinars from KOLs providing thought provoking and educational talks on disparate areas of non-malignant haematology. KOLs are reimbursed for their time. The Limbic reimburse HaemSTAR if attendees fill in feedback surveys. PODCAST Received funding from Sobi to purchase equipment and fund external agency to provide sound engineering expertise. Monthly journal club podcast on latest papers in non-malignant haematology. Includes author interviews and discussion with experts. BSH CONFERENCE SESSION HaemSTAR now has a session at BSH (in association with UK-TReN) in the form of Dragon's Den. HaemSTAR funded the prizes in this session.
Statement confirming whether the trustees have had regard to the guidance issued by the Charity Commission on public benefit	Para 1.18	N/A – not relevant to our charitable purposes

Additional information (optional)

You may choose to include further statements where relevant about:

	SORP reference	
Policy on grant making	Para 1.38	N/A
Policy on social investment including program related investment	Para 1.38	N/A
Contribution made by volunteers	Para 1.38	N/A

Other		N/A

Achievements and Performance

	SORP reference	
Summary of the main achievements of the charity, identifying the difference the charity's work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole.	Para 1.20	FUNDING Received the following grants: - Legacy fund from 2022 ISTH conference in London (see above): £28,810. - Podcast support (unrestricted educational grant) from Sobi: £19,200 - Administrative support (unrestricted grant) from Takeda: £5,000 PUBLICATIONS Nicolson PLR, Belete M, Hawes R, Fowler N, Toh CH. Alternative routes into clinical research: a guide for early career doctors. BMJ. 2024;385:e076414.

Additional information (optional)

You may choose to include further statements where relevant about:

Achievements against objectives set	Para 1.41	
Performance of fundraising activities against objectives set	Para 1.41	
Investment performance against objectives	Para 1.41	
Other		

Financial Review

Review of the charity's financial position at the end of the period	Para 1.21	Amount held at start of reporting period: £80,693 Income from all sources (including interest): £54,928 All spending: £39,541 Amount held at the end of the reporting period: £96,081
Statement explaining the policy for holding reserves stating why they are held	Para 1.22	Cash in bank at 31/5/24 was £69,598 in unrestricted funds and £26,492 in restricted funds for ISTH Legacy fund spending committed spending for 2024-25 comprises website hosting fees of approximately £350, podcast hosting fees of £200, accountancy fees of ~£150 and administration costs (paid for the time of our administrator) of ~£3000. This is all covered by the administrative grant of £5000 from Takeda and does not represent a financial risk. We also aim to apply for additional sponsorship of the podcast for when the Sobi sponsorship ends in 2025. In 2023-24 we expanded our ability to fund registrars to attend conferences. £19,200 of this comes from the ISTH Legacy fund and we are able to use this until 2026. It is unlikely that costs will exceed this figure. The educational webinars are a source of an approximately £1200 annual cost. This is voluntary however and can be stopped if there are insufficient funds. There is an approximate £30,000 cost still associated with RAPIDO that is waiting to be paid to the University of Birmingham but this is covered by the Astra Zeneca grant from last year. The HaemSTAR Update Day is now a recurring event but this is organised through Hartley Taylor and they secure industry support for the meeting. The only HaemSTAR costs are voluntary and will not go ahead if there are insufficient funds. All the projects currently active are fully funded. However we would like to run unfunded projects by using money underspent from other projects and also pump prime our pipeline by employing a project/data manager through the University of Birmingham at a cost of approximately £70,000 per year. This is not yet feasible and will not go ahead unless there are sufficient funds. The funding for this will be reviewed on an annual basis and no commitments beyond 1 year will be made to ensure there is no financial risk to the charity.
Amount of reserves held	Para 1.22	£0
Reasons for holding zero reserves	Para 1.22	We do not have a reserve policy.
Details of fund materially in deficit	Para 1.24	N/A
Explanation of any uncertainties about the charity continuing as a going concern	Para 1.23	Nil uncertainties. N/A

Additional information (optional)

You may choose to include further statements where relevant about:

The charity's principal sources of funds (including any fundraising)	Para 1.47	

Investment policy and objectives including any social investment policy adopted	Para 1.46	
A description of the principal risks facing the charity	Para 1.46	
Other		

Structure, Governance and Management

Description of charity's trusts:		Nil
Type of governing document (trust deed , royal charter)	Para 1.25	Constitution
How is the charity constituted? (e.g unincorporated association , CIO)	Para 1.25	Unincorporated Association
Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees	Para 1.25	Nil.

Additional information (optional)

You may choose to include further statements where relevant about:

Policies and procedures adopted for the induction and training of trustees	Para 1.51	
The charity's organisational structure and any wider network with which the charity works	Para 1.51	
Relationship with any related parties	Para 1.51	
Other		

Reference and Administrative details

Charity name	HaemSTAR: Haematology Specialist Training, Audit and Research
Other name the charity uses	HaemSTAR
Registered charity number	1199224
Charity's principal address	Office 129, Institute of Biomedical Research Edgbaston Birmingham B15 2TT

Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1	Phillip LR Nicolson	President		
2	Richard J Buka	Chair		
3	Andrew J Doyle			
4	Emily Millen			
5	Tom Bull			
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				

Corporate trustees – names of the directors at the date the report was approved

[illegible]

Name of trustees holding title to property belonging to the charity

[illegible]

Funds held as custodian trustees on behalf of others

Description of the assets held in this capacity	Nil
Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity's objects	N/A
Details of arrangements for safe custody and segregation of such assets from the charity's own assets	N/A

Additional information (optional)

Names and addresses of advisers (Optional information)

Type of adviser	Name	Address

Name of chief executive or names of senior staff members (Optional information)

--

Exemptions from disclosure

Reason for non-disclosure of key personnel details

N/A


Other optional information

--

Declarations

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

Signature(s)		
Full name(s)	Dr Phillip LR Nicolson	
Position (eg Secretary, Chair, etc)	President	
Date	21/3/2025	



CHARITY COMMISSION
FOR ENGLAND AND WALES

HaemSTAR: Haematology Specialty Training Audit and
Research

1199224

Receipts and payments accounts

CC16a

For the period from	01/06/2023	To	31/05/2024
------------------------	------------	----	------------

Section A Receipts and payments

	Unrestricted funds to the nearest £	Restricted funds to the nearest £	Endowment funds to the nearest £	Total funds to the nearest £	Last year to the nearest £
A1 Receipts					
ISTH Legacy Fund Award 30/6/2023		28 810	-	28 810	35 200
Sobi Podcast Sponsorship 12/12/2023 (inv 20231129 Sobi Podcasts)	19 200	-	-	19 200	17 600
35-day Savings Interest (29/12/23)	103			103	
Takeda Non-specific grant 9/1/24	5 000	-	-	5 000	-
35-day Savings Interest (31/01/24)	197			197	
35-day Savings Interest (29/02/24)	174			174	
Business Reserve Interest 29/2/24	1			1	
35-day Savings Interest (28/3/24)	168			168	
Business Reserve Interest 28/3/24	11			11	
95-day Savings Interest (28/3/24)	32			32	
Business Reserve Interest 30/4/24	13			13	
35-day Savings Interest (30/4/24)	199			199	
95-day Savings Interest (30/4/24)	38			38	
Business Reserve Interest 31/5/24	12			12	
35-day Savings Interest (31/5/24)	185			185	
95-day Savings Interest (31/5/24)	36			36	
Pip Nicolson (Charitable Donation) 2/4/24	750	-	-	750	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
Sub total (Gross income for AR)	26 118	28 810	-	54 928	52 800
A2 Asset and investment sales, (see table).					
	-	-	-	-	
	-	-	-	-	-
Sub total	-	-	-	-	-
Total receipts	26 118	28 810	-	54 928	52 800

A3 Payments

Squarespace (Web domain) 6/6/2023	19	-	-	19	23
University of Birmingham (RAPIDO 1 inv 71049181) 16/6/2023	20 000	-	-	20 000	268
Squarespace (Web domain) 6/7/2023	19	-	-	19	2 786
Squarespace (Web domain) 6/8/2023	19	-	-	19	240
RCPATH (Podcast CPD Accreditation) 14/8/2023	250	-	-	250	543
Squarespace (Web domain) 6/9/2023	19	-	-	19	45
Rich Buka (Ableton Software for Podcast) 12/9/2023	129	-	-	129	155
University of Birmingham (RAPIDO 2 inv 71345158) 6/10/2023	10 000	-	-	10 000	189
Squarespace (Web domain) 6/10/2023	19			19	82
Amazon (Ian Roberts, Limbic Webinar Thank you Payment 6/10/2023)	100			100	338
Squarespace (Web domain) 6/11/2023	19			19	19
Amazon (Noemi Roy, Limbic Webinar Thank you Payment 27/11/2023)	100			100	19
Squarespace (Web domain) 6/12/2023	19			19	19
Squarespace (Web domain) 8/1/2024	19			19	26
Helen Apperley (Jun 23-Jan 24 Admin support, 90 hrs at £15 ph) 15/1/24	1 350			1 350	250
Maryam Subhan (ISTH Legacy Fund, 15/1/24)		1 418		1 418	19
Acast (Podcast hosting annual fee, 2023-24)	145			145	
Amazon (audio equipment for podcast: XLR microphone cable) 24/1/24	11			11	
Amazon (Audio equipment for podcast: condenser microphone, pop filter, mic stand, 25/1/24)	382			382	
Amazon (Mark Thomas & Sutesh Sivapalaratnam, Limbic Webinar Thank you Payments x2 29/1/24)	200			200	
Squarespace (Web domain) 6/2/2024	19			19	
Amazon (Angela Weyland HaemSTAR update day speaker thank you payment 20/2/24)	150			150	
Amazon (Dan Hart, A Rutherford, Sophie Evans, M Badat. HaemSTAR update day speaker thank you payments x4 26/2/24)	400			400	
Squarespace (Web domain) 26/2/2024	3			3	
Squarespace (Web domain) 6/3/24	29			29	
Olga Tsiamita (HaemSTAR update day travel. 13/3/24)	177			177	
J Schofield (HaemSTAR update day travel. 13/3/24)	126			126	
Julia Wolf (HaemSTAR update day travel. 13/3/24)	174			174	
Stephen Hibbs (HaemSTAR update day travel. 13/3/24)	57			57	
Helen Apperley (postage reimbursement. 13/3/24)	14			14	
Giulia Simini (HaemSTAR update day travel. 13/3/24)	147			147	
Ethan Troy-Barnes (HaemSTAR update day travel. 13/3/24)	134			134	
Catrin Cox (BSH Travel 13/3/24)	120			120	
Christina Crossette-Thambiah (BSH Travel 13/3/24)	120			120	
Joe Apperley (Podcast editing x2 episodes) 26/3/24	680			680	
Amazon (Tom Bullock, Limbic webinar thank you payment)	100			100	
Squarespace (Web domain) 7/3/2024	29			29	

John Chadwick (ISTH Legacy Fund) 5/4/2024		750		750	
Willows Accountancy (Preparation of Annual Accounts) 5/4/2024	120			120	
Squarespace (Web domain) 8/4/2024	29			29	
BACARO, Liverpool (BSH Reps Meal) 30/4/24	420			420	
Amazon (Richard Riley & Bernard Laemmle, Limbic Webinar Thank you Payments x2 20/05/2024)	200			200	
Gill Lowe (BSH Session Prize reimbursement, 28/5/24)	100			100	
Elena Torre (ISTH Legacy Fund, BSH 28/5/24)		500		500	
Richard Buka (BSH Hotel/Travel, 28/5/24)	107			107	
Lottie Hickman (BSH Hotel/Travel, 28/5/24)	198			198	
Yen Huan Yeo (ISTH Legacy Fund, BSHT 28/5/24)		400		400	
		-	-	-	-
Sub total	36 473	3 068	-	39 541	5 022
A4 Asset and investment purchases, (see table)					
	-	-	-	-	-
	-	-	-	-	-
Sub total	-	-	-	-	-
Total payments	36 473	3 068	-	39 541	5 022
Net of receipts/(payments)	- 10 355	25 742	-	15 388	47 778
A5 Transfers between funds	-	-	-	-	-
A6 Cash funds last year end	80 693	-	-	80 693	-
Cash funds this year end	70 338	25 742	-	96 081	47 778

Section B Statement of assets and liabilities at the end of the period

Categories	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
B1 Cash funds	Money in bank account (31.5.24) Total cash funds (agree balances with receipts and payments account(s))	96 081 - - - 96 081 Agreement Error	- - - - - Agreement Error	- - - - - OK
B2 Other monetary assets	Details	- - - - - - -	- - - - - - -	- - - - - - -
B3 Investment assets	Details	Fund to which asset belongs	Cost (optional) - - - - -	Current value (optional) - - - - -
B4 Assets retained for the charity's own use	Details	Fund to which asset belongs	Cost (optional) - - - - - - - - -	Current value (optional) - - - - - - - - -
B5 Liabilities	Details	Fund to which liability relates	Amount due (optional) - - - - -	When due (optional)
Signed by one or two trustees on behalf of all the trustees	Signature	Print Name	Date of approval	



CHARITY COMMISSION
FOR ENGLAND AND WALES

Independent examiner's report on the accounts

Section A

Independent Examiner's Report

Report to the trustees

Charity Name

Haemstar: Haematology Speciality Training Audit and Research

On accounts for the year ended

31/05/2024

Charity no
(if any)

1199224

Set out on pages

(remember to include the page numbers of additional sheets)

I report to the trustees on my examination of the accounts of the above charity ("the Trust") for the year ended 31 May 2024.

Responsibilities and basis of report

As the charity's trustees, you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination which gives me cause to believe that in, any material respect:

- the accounting records were not kept in accordance with section 130 of the Charities Act; or
- the accounts did not accord with the accounting records; or
- the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

** Please delete the words in the brackets if they do not apply.*

Signed:

Mark Fellows

Date:

18 March 2025

Name:

Mark Fellows (Willows Accountancy Ltd)

Relevant professional
qualification(s) or body
(if any):

Fellow Member of Association of Accounting Technicians

Address:

172 Watling Street, Bridgtown, Staffordshire, WS11 0BD

Section B**Disclosure**

Only complete if the examiner needs to highlight material matters of concern (see CC32, Independent examination of charity accounts: directions and guidance for examiners).

Give here brief details of any items that the examiner wishes to disclose.